p15和nm23基因在子宫内膜癌中的表达

Expression of p15 and nm23 Genes in Uterine Endometrial Carcinoma

目的:探讨p15和nm23在子宫内膜癌发生、发展中的作用。方法:应用免疫组织化学SP法检测60例子宫内膜癌组织及10例正常子宫内膜组织中p15和nm23的表达,并分析两基因表达与子宫内膜癌临床病理学参数的关系。结果:p15在子宫内膜癌组织和正常子宫内膜组织中的阳性表达率分别为66.7%和100%,差异有统计学意义(P<0.01);nm23在子宫内膜癌组织和正常子宫内膜组织中的阳性表达率分别为60%和70%,差异无统计学意义(P>0.05);p15在不同组织学分级子宫内膜癌组织中的阳性表达率差异有统计学意义(P<0.05);nm23在不同临床分期和有无淋巴结转移子宫内膜癌组织中的阳性表达率差异有统计学意义(P<0.05);Logistic回归分析结果示组织学分级是p15的表达的影响因素(OR=8.825,95%CI为2.214～35.178,P<0.05),未见影响nm23表达的因素入选;p15和nm23在子宫内膜癌中的表达呈正相关(rs=0.754,P<0.01)。结论:p15的表达对判断子宫内膜癌患者的预后具有重要意义。

Objective：To explore the role of p15 gene and nm23 gene in the generation and development of human uterine endometrial carcinoma.Methods：The expressions of p15 and nm23 were detected by immunohistochemistry S-P method in 60 specimens of uterine endometrial carcinoma and 10 specimens of normal endometrial tissues.The relation between the genes and the clinical pathology was studied in human uterine endometrial carcinoma.Results：The positive expression rates of p15 were significantly different between endometrial carcinoma and normal endometrial tissues（66.7% and 100%,P〈 0.01）.The positive expression rates of nm23 were 60% and 70% between endometrial carcinoma and normal endometrial tissues（P〉 0.05）.By chi-square test,the positive expression of p15 was significantly related with the pathological grades（P 〈0.05）.The expression of nm23 was significantly related with operation-pathological stages and lymph node metastasis（P〈 0.05）.By logistic regression analysis,there was positive correlation between the expression of p15 and pathological grades in endometrial carcinoma（OR=8.825,95%CI was 2.214-35.178,P〈 0.05）.There was no correlation between the expression of nm23 and all the clinic-pathology parameters of uterine endometrial carcinoma.By rank correlation test,there was positive correlation between p15 expression and nm23 expression in the endometrial carcinoma（rs=0.754,P〈 0.01）.Conclusion：The expression of p15 has an important meaning in judging prognosis evaluation of endometrial carcinoma.